Drug Type Monoclonal antibody |
Synonyms HFB 2027, HFB2027 |
Target |
Action agonists |
Mechanism TNFR2 agonists(Tumor necrosis factor receptor superfamily member 1B agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Immune System Diseases | Preclinical | United States | 01 May 2025 | |
Inflammation | Preclinical | United States | 01 May 2025 |